Athlete's Stage 4 Cancer Shock

Dave Nitsche, an ultra-runner and triathlete, faced a life-altering diagnosis just before his 50th birthday. Experiencing sudden vision loss, he was found to have stage 4 lung cancer that had metastasized to his eye, bones, liver, kidneys, and brain.

Despite never smoking and having no family history, Nitsche received a grim prognosis of 1- to 2-year life expectancy. Traditional treatments were deemed ineffective, but targeted therapies offered a new path. He has since been on several medications, including Gilotrif, Tagrisso, and currently Rybrevant, managing his condition for seven years.

Nitsche's experience highlights the challenges of diagnosing non-small cell lung cancer (NSCLC) in non-smokers, which accounts for 85% of lung cancer cases. Unlike the common perception, NSCLC can be asymptomatic or have mild symptoms, leading to late-stage detection.

Remarkably, Nitsche has remained physically active throughout his treatment, cycling to appointments and training for endurance events. He credits his high VO2 max levels and a positive mindset for helping him endure treatment and live beyond his initial prognosis, emphasizing perseverance and living day by day.